Anaesthetic Efficacy of 2% Mepivacaine Versus 4% Articaine With Symptomatic Irreversible Pulpitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

330 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-12-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this randomized, double-blinded, clinical trial was to assess the effect of 3.6 mL 2% mepivacaine hydrochloride with 1:100,000 epinephrine compared to 3.4 mL 4% articaine hydrochloride with 1:100,000 epinephrine on the success of the inferior alveolar nerve block for patients with symptomatic irreversible pulpitis in mandibular molars.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Anesthetic Efficacy of 2% Mepivacaine Versus 4% Articaine

NCT03725579

Symptomatic Irreversible Pulpitis

UNKNOWN PHASE2/PHASE3

Volume Increase Versus Supplemental 4% Articaine Buccal Infiltration on Mepivacaine Inferior Alveolar Nerve Block Success

NCT05238727

Symptomatic Irreversible Pulpitis

UNKNOWN NA

Two Approaches in Enhancing the Efficacy of Inferior Alveolar Nerve Block During Treatment of Mandibular First Permanent Molars With Symptomatic Irreversible Pulpitis

NCT05427903

Pain, Procedural

UNKNOWN NA

Anesthetic Efficacy of 1,8mL and 3,6mL of Articaine in Inferior Alveolar Nerve Block in Irreversible Pulpitis

NCT02422823

Pulpitis

COMPLETED NA

Anesthetic Efficacy of 1.8 ml Versus 3.6 ml of 4% Articaine Buccal Infiltration

NCT06119139

Symptomatic Irreversible Pulpitis

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of this randomized, double-blinded, clinical trial was to assess the effect of 3.6 mL 2% mepivacaine hydrochloride with 1:100,000 epinephrine compared to 3.4 mL 4% articaine hydrochloride with 1:100,000 epinephrine on the success of the inferior alveolar nerve block for patients with symptomatic irreversible pulpitis in mandibular molars. Patients were clinically and radiographically examined and their eligibility assessed and preoperative pain was measured using the numerical rating scale (NRS). Patients were randomly assigned to one of 2 groups: experimental group (2% mepivacaine) and the control group (4% articaine). After 15 minutes of the inferior alveolar nerve block (IANB), patients reporting lip numbness had their molars accessed. No-to-mild pain response was considered success during root canal preparation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Symptomatic Irreversible Pulpitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mepivacaine

IANB using 3.6 ml of 2% mepivacaine hydrochloride with 1:100,000 epinephrine.

Group Type EXPERIMENTAL

Mepivacaine

Intervention Type DRUG

IANB using 3.6 ml of 2% mepivacaine hydrochloride with 1:100,000 epinephrine.

Articaine

IANB using 3.4 ml of 4% articaine hydrochloride with 1:100,000 epinephrine.

Group Type ACTIVE_COMPARATOR

Articaine

Intervention Type DRUG

IANB using 3.4 ml of 4% articaine hydrochloride with 1:100,000 epinephrine.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mepivacaine

IANB using 3.6 ml of 2% mepivacaine hydrochloride with 1:100,000 epinephrine.

Intervention Type DRUG

Articaine

IANB using 3.4 ml of 4% articaine hydrochloride with 1:100,000 epinephrine.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients in good health (American Society of Anesthesiologists Class I or II).
* Patients having symptomatic irreversible pulpitis in one of their mandibular molars.
* Age range between 18 to 50 years.
* Patients who can understand Numerical Rating Scale (NRS).
* Positive patient acceptance and the ability to sign an informed consent.

Exclusion Criteria

* Pregnant females.
* Patients allergic to articaine, mepivacaine and/or any used medication or material.
* Patients having active sites of pathosis in the area of injection.
* Patients having active pain in more than one molar.
* Patients who had taken analgesics in the 12 hours preceding treatment.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No